Aktuellt
SENASTE
Redeye lowers its sales estimates on all time horizons for Sedana Medical following the Q2 report, rendering downward changes to our fair value range. We see a continuous uncertainty in its sales growth prospects in the medium term, further supported by the company’s scrapped 2025e sales target, which is replaced by other short-term targets. Still, the US could have significant upside potential if the company successfully manages its EU roll-out.
LÄS MER
